Boehringer Ingelheim and Microsoft launched an early-stage collaboration to develop AI-powered “digital patient twins” for clinical-trial planning. The effort aims to simulate disease progression and treatment response using clinical and other relevant data. The companies are exploring whether these simulated models can serve as synthetic or hybrid control groups, with goals that include lowering the number of patients needed in control arms, accelerating evidence generation, and improving trial design. Boehringer’s spokesman Michael Kühnapfel said the “real promise” is making better use of data, while also stressing that any expansion would require validation and applicable regulatory approvals. The collaboration comes after the U.S. HHS introduced the SURPASS program, which includes uses for digital patient twins in tasks such as trial design feasibility. The deal also fits a broader wave of trial-focused AI partnering, including other technology vendors tied to recruitment and study execution. For sponsors, the work signals how platform AI may move from analytics into trial architecture—if regulatory and scientific validation clear the path from feasibility to acceptability.